TY - JOUR
T1 - TLR9 provokes inflammation in response to fetal DNA
T2 - Mechanism for fetal loss in preterm birth and preeclampsia
AU - Scharfe-Nugent, Andrea
AU - Corr, Sinéad C.
AU - Carpenter, Susan B.
AU - Keogh, Louise
AU - Doyle, Brendan
AU - Martin, Cara
AU - Fitzgerald, Katherine A.
AU - Daly, Sean
AU - O'Leary, John J.
AU - O'Neill, Luke A.J.
PY - 2012/6/1
Y1 - 2012/6/1
N2 - Preterm birth, the major cause of neonatal mortality in developed countries, is associated with intrauterine infections and inflammation, although the exact mechanisms underlying this event are unclear. In this study, we show that circulating fetal DNA, which is elevated in pregnancies complicated by preterm labor or preeclampsia, triggers an inflammatory reaction that results in spontaneous preterm birth. Fetal DNA activates NF-κB, shown by IκBα degradation in human PBMCs resulting in production of proinflammatory IL-6. We show that fetal resorption and preterm birth are rapidly induced in mice after i.p. injection of CpG or fetal DNA (300 μg/dam) on gestational day 10-14. In contrast, TLR9 -/- mice were protected from these effects. Furthermore, this effect was blocked by oral administration of the TLR9 inhibitor chloroquine. Our data therefore provide a novel mechanism for preterm birth and preeclampsia, highlighting TLR9 as a potential therapeutic target for these common disorders of pregnancy.
AB - Preterm birth, the major cause of neonatal mortality in developed countries, is associated with intrauterine infections and inflammation, although the exact mechanisms underlying this event are unclear. In this study, we show that circulating fetal DNA, which is elevated in pregnancies complicated by preterm labor or preeclampsia, triggers an inflammatory reaction that results in spontaneous preterm birth. Fetal DNA activates NF-κB, shown by IκBα degradation in human PBMCs resulting in production of proinflammatory IL-6. We show that fetal resorption and preterm birth are rapidly induced in mice after i.p. injection of CpG or fetal DNA (300 μg/dam) on gestational day 10-14. In contrast, TLR9 -/- mice were protected from these effects. Furthermore, this effect was blocked by oral administration of the TLR9 inhibitor chloroquine. Our data therefore provide a novel mechanism for preterm birth and preeclampsia, highlighting TLR9 as a potential therapeutic target for these common disorders of pregnancy.
UR - https://www.scopus.com/pages/publications/84862059620
U2 - 10.4049/jimmunol.1103454
DO - 10.4049/jimmunol.1103454
M3 - Article
C2 - 22544937
AN - SCOPUS:84862059620
SN - 0022-1767
VL - 188
SP - 5706
EP - 5712
JO - Journal of Immunology
JF - Journal of Immunology
IS - 11
ER -